Merck drops as heart drug falls short in study

The failure raises more questions about treatments designed to raise good cholesterol levels.

By Dec 20, 2012 4:25PM

corbisA heart drug being developed by Merck (MRK) failed in a clinical trial, dashing hopes for a new treatment option and a potentially big-selling product for the pharmaceutical giant.

The drug, Tredaptive, is designed to raise good cholesterol levels to help ward off heart attacks and other cardiovascular events. Although it was rejected by the U.S. Food and Drug Administration in 2008 because the agency felt it need more studies, it is already approved in Europe. Merck hoped to reapply for U.S. market approval providing that the large study showed effectiveness for the therapy. 

But in a study of almost 26,000 people, Tredaptive did not meet the study goal of significantly reducing the risk of heart attack or stroke in vulnerable patients. The drug, which includes the active ingredient niacin, was tested in combination with statins, which are common cholesterol-lowering drugs. Niacin, a type of B vitamin, is one of the oldest treatments to control cholesterol levels.

Shares of Merck fell 3% to $42.48 in midday trading Thursday. The stock is up 15% in the past year.

In addition to the reported futility of the drug, the researchers found "a statistically significant increase in the incidence of some types of non-fatal serious adverse events." The company wasn't any more specific about the safety issues, but it said it was working with an independent research team at Oxford University to share the study data with regulators in the countries where the drug is approved.

"Based on the current understanding of these new data and until further analysis can be completed, Merck is recommending that providers not start new patients on Tredaptive," Merck says in a statement.

The news Thursday also raises more questions about the use of niacin as a means to raise good cholesterol to protect against heart attacks. In early 2011, the U.S. government stopped its own study of Abbott Laboratories (ABT) drug Niaspan in combination with the statin simvastatin as a therapy to prevent heart attacks. Government researchers said the drug combo didn't work and it may have been linked to strokes in a small group of patients in the study. Niaspan is approved in the U.S. to treat cholesterol levels. (Simvastatin, incidentally, is the generic name for Merck's branded cholesterol drug Zocor.)   

Tredaptive (called Cordaptive when Merck sought U.S. approval a few years ago) was considered by some Wall Street analysts to be a potentially big-selling product.

In September, Leerink Swann analyst Seamus Fernandez slashed a sales estimate for the Merck drug in half to $800 million in annual revenue by 2018. The analyst said he adjusted his estimate after consulting with leading doctors who felt that Tredaptive's safety profile was no different than Niaspan's. (Read Niaspan's label here.) Tredaptive includes a drug, laropiprant, designed to offset the niacin side effect of facial flushing.

Fernandez gave Merck's study of Tredaptive a 50-50 chance of success. He said the release of the study data would be a "potential watershed event" for Merck.

Other analysts had more conservative estimates for Tredaptive. Credit Suisse analyst Catherine Arnold projected peak annual sales of $350 million by 2020.

Merck officials seemed to be at a loss for words to explain the drug's failure.

"We are committed to working closely with the independent research team at Oxford University and with regulatory agencies to understand the results and determine next steps," Merck's R&D chief Peter S. Kim says in a statement.

More from Minyanville



Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

124 rated 1
266 rated 2
452 rated 3
702 rated 4
671 rated 5
604 rated 6
640 rated 7
495 rated 8
267 rated 9
158 rated 10

Top Picks




Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.